BioSpace News Archive

Here is a summary of the latest news about bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease.

Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced the selection of a development candidate for the Company’s program targeting KAT6, an epigenetic target that is dysregulated in breast cancer and other cancers.

Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, will discuss the Company’s 2024 strategic priorities and anticipated milestones at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, at 4:30 p.m. PST.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced Pascal Touchon, President and Chief Executive Officer of Atara, will present the Company’s 2023 accomplishments across strategic priorities and key upcoming milestones at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11 at 9:45 a.m. PST / 12:45 p.m. EST.

Allurion Announces Preliminary Fourth Quarter and Full Year 2023 Results and Provides 2024 Outlook.

VIVUS LLC announced pipeline updates and program milestones.

Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the full year ended December 31, 2023.

Okami Medical Inc. announced the appointment of Rhonda Robb as President and Chief Executive Officer.

PrognomiQ today announced promising results from the largest, deep multi-omics study conducted to date.

Arbutus Biopharma Corporation announced its 2024 business outlook including its clinical development milestones to advance its HBV pipeline and a financial update.